Literature DB >> 29312693

The Canakinumab Antiinflammatory Thrombosis Outcome Study trial-the starting gun has fired.

David Crossman1, Alexander Rothman2.   

Abstract

Entities:  

Year:  2017        PMID： 29312693      PMCID： PMC5756992          DOI： 10.21037/jtd.2017.11.96

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   3.005


× No keyword cloud information.
  21 in total

1.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Authors:  Paul M Ridker; Brendan M Everett; Tom Thuren; Jean G MacFadyen; William H Chang; Christie Ballantyne; Francisco Fonseca; Jose Nicolau; Wolfgang Koenig; Stefan D Anker; John J P Kastelein; Jan H Cornel; Prem Pais; Daniel Pella; Jacques Genest; Renata Cifkova; Alberto Lorenzatti; Tamas Forster; Zhanna Kobalava; Luminita Vida-Simiti; Marcus Flather; Hiroaki Shimokawa; Hisao Ogawa; Mikael Dellborg; Paulo R F Rossi; Roland P T Troquay; Peter Libby; Robert J Glynn
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

2.  Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies).

Authors:  Antonio Abbate; Michael Christopher Kontos; Nayef Antar Abouzaki; Ryan David Melchior; Christopher Thomas; Benjamin Wallace Van Tassell; Claudia Oddi; Salvatore Carbone; Cory Ross Trankle; Charlotte Susan Roberts; George Herman Mueller; Michael Lucas Gambill; Sanah Christopher; Roshanak Markley; George Wayne Vetrovec; Charles Anthony Dinarello; Giuseppe Biondi-Zoccai
Journal:  Am J Cardiol       Date:  2014-11-13       Impact factor: 2.778

3.  Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.

Authors:  Paul M Ridker; Jean G MacFadyen; Tom Thuren; Brendan M Everett; Peter Libby; Robert J Glynn
Journal:  Lancet       Date:  2017-08-27       Impact factor: 79.321

Review 4.  Anti cytokine therapy in chronic inflammatory arthritis.

Authors:  Charlotte Thompson; Ruth Davies; Ernest Choy
Journal:  Cytokine       Date:  2016-08-03       Impact factor: 3.861

5.  The in vivo effects of interleukin 1. I. Bone marrow cells are induced to cycle after administration of interleukin 1.

Authors:  R Neta; M B Sztein; J J Oppenheim; S Gillis; S D Douches
Journal:  J Immunol       Date:  1987-09-15       Impact factor: 5.422

Review 6.  Inflammasome and cytokine blocking strategies in autoinflammatory disorders.

Authors:  Monika Moll; Jasmin B Kuemmerle-Deschner
Journal:  Clin Immunol       Date:  2013-04-19       Impact factor: 3.969

Review 7.  Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials.

Authors:  Alberico Luigi Catapano; Angela Pirillo; Giuseppe Danilo Norata
Journal:  Br J Pharmacol       Date:  2017-05-05       Impact factor: 8.739

8.  Differential IL-1 signaling induced by BMPR2 deficiency drives pulmonary vascular remodeling.

Authors:  Josephine Pickworth; Alexander Rothman; James Iremonger; Helen Casbolt; Kay Hopkinson; Peter M Hickey; Santhi Gladson; Sheila Shay; Nicholas W Morrell; Sheila E Francis; James D West; Allan Lawrie
Journal:  Pulm Circ       Date:  2017-09-22       Impact factor: 3.017

9.  Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension.

Authors:  Jules Hernández-Sánchez; Louise Harlow; Colin Church; Sean Gaine; Emily Knightbridge; Kate Bunclark; Dee Gor; Alun Bedding; Nicholas Morrell; Paul Corris; Mark Toshner
Journal:  Pulm Circ       Date:  2017-09-28       Impact factor: 3.017

10.  Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding.

Authors:  Janet Chamberlain; Sheila Francis; Zoe Brookes; Gary Shaw; Delyth Graham; Nicholas J Alp; Steven Dower; David C Crossman
Journal:  PLoS One       Date:  2009-04-06       Impact factor: 3.240
View more
  1 in total

1.  Interleukin-1 beta inhibition with canakinumab and reducing lung cancer-subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS).

Authors:  David Crossman; Alexander M K Rothman
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 3.005
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.